Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells (Ankara University)
- Development stage
- Unknown
- Lead developer
- Ankara University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) is an investigational cell therapy developed by researchers at Ankara University and Bioretina Inc. for the treatment of retinitis pigmentosa (RP). The therapy involves the subtenon injection of mesenchymal stem cells harvested from the Wharton's jelly of the umbilical cord. These cells are thought to function through paracrine mechanisms, secreting exosomes that contain various growth factors and neurotrophins. This secretome is intended to provide neuroprotection, reduce apoptosis, and reactivate degenerated photoreceptor cells that are in a dormant phase, regardless of the underlying genetic mutation causing the disease. Clinical development has reached Phase 3, where the cells have been evaluated both as a monotherapy and in combination with repetitive electromagnetic stimulation (rEMS) delivered via the Magnovision device.
- Other names
- umbilical cord-derived Wharton's jelly mesenchymal stem cellssubtenon WJ-MSC
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells (Ankara University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells (Ankara University).